Innovation Testing in U.S. Healthcare: Ethical Dilemmas
This paper examines "innovation testing" as an emerging issue in U.S. healthcare and the two ethical dilemmas it creates: one centered on scientific progress in laboratories and clinics, and another involving healthcare access, financing, and regulation in policy arenas. Drawing on sources spanning cancer survival rates, R&D spending, waiting times, and patient satisfaction, the paper compares the U.S. healthcare system with those of European nations and Canada. It concludes by recommending the creation of Healthcare Innovation Zones and market-based financing reforms—including tax credits and private health-financing options—as approaches that preserve incentives for innovation while expanding access.
- Introduction: Defines innovation testing and its two ethical dilemmas
- United States vs. Europe on Innovation Testing: Compares U.S. and international health R&D spending
- Comparative Health Outcomes and Access: Cancer survival, chronic disease, and waiting time data
- Patient Satisfaction and Technology Access: Satisfaction rates and medical imaging availability compared
- American Leadership in Healthcare Innovation: U.S. clinical trials, Nobel Prizes, and medical advances
- Conclusion and Recommendations: Healthcare Innovation Zones and market-based reform proposals
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper marshals a wide range of empirical citations — cancer mortality statistics, waiting-time data, and R&D spending figures — to ground its ethical argument in concrete evidence rather than abstract claims.
- It maintains a balanced structure by presenting both critiques of U.S. healthcare spending efficiency and defenses of American health outcomes before moving to recommendations.
- The conclusion ties the analytical sections together by translating comparative findings into specific, actionable policy recommendations, including the Healthcare Innovation Zone concept.
Key academic technique demonstrated
The paper demonstrates effective synthesis of multiple sources across a single argumentative thread. Rather than summarizing each source independently, the author layers evidence from different researchers — Christensen, Nussbaum, Atlas, and O'Neill — to build a cumulative case about the strengths and weaknesses of U.S. healthcare innovation, then resolves the tension in the recommendations section.
Structure breakdown
The paper opens with a framing introduction that defines "innovation testing" and its two ethical dilemmas. The second section compares U.S. and European R&D spending. The third and fourth sections present comparative outcome data — cancer survival, chronic disease access, waiting times, and patient satisfaction. A fifth section argues for American dominance in medical innovation. The conclusion synthesizes findings and proposes the Healthcare Innovation Zone model and private-market reforms as solutions.
Introduction
According to Business Services Industry (2007), the medical technology industry is an ever-growing one, constantly fuelled by increasing demand from the medical community. Ground-breaking innovations such as drug-eluting stents, cardiac rhythm management devices, joint replacements, intravascular ultrasound, endoscopes, minimally invasive surgical devices, surgical staplers, and lasers have increased longevity and life expectancy. Business Services Industry (2007) further declares that these innovations have dramatically improved overall treatment options for doctors and other medical practitioners by reducing associated effort and delivery time.
Lechleiter (2009) declares that "innovation testing" is an emerging issue posing two new ethical dilemmas in U.S. healthcare. According to Lechleiter, the first dilemma is set in laboratories and clinics, and it is a hopeful story of how innovation may continue to improve human health; while the other dilemma is set in Washington conference rooms and corporate boardrooms, and it concerns the reform of healthcare access, financing, and regulation. As a scientist who leads what he calls "the last unmerged large pharmaceutical company," Lechleiter (2009) is a rare player who moves between these two arenas — though he does so with growing concern.
According to Lechleiter (2009), inventions such as biosynthetic human insulin, bone-forming agents for treating osteoporosis, new cancer therapies, and a first-ever treatment for severe sepsis have gone from glimmers of intuition to everyday medical tools. Lechleiter appreciates that these innovations — made possible through "innovation testing" — have transformed the most basic expectations of human life. Notably, the average life expectancy at birth in the U.S. is now 78, compared to 57 in 1928. To support the claim that rising life expectancy can be attributed to the availability of new medicines, Lechleiter cites a study by Columbia University economist Frank Lichtenberg, who found that new medicines accounted for 40% of the increase in life expectancy across more than 50 countries during the last two decades of the 20th century.
Create your account
Always verify citation format against your institution’s current style guide requirements.